National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sent this bulletin at 06/20/2019 10:30 AM EDT
NIDDK Health Information News
At the American Diabetes Association's 79th Scientific Sessions, held June 7-11, NIDDK participated in presentations and poster sessions, presenting invaluable information for health care professionals and researchers based on evidence obtained from NIDDK-funded studies. It was an opportunity to share ideas and learn from leading diabetes experts about the significant advances in diabetes research, treatment, and care over the course of five days.
Here are some highlights:
NDEP Symposium: How Do We Focus on Consensus Rather Than Controversy?
Featuring NIDDK Director Dr. Griffin Rodgers as one of six panelists, this symposium focused on Guiding Principles for the Care of People With or at Risk for Diabetes, discussing issues in diabetes prevention and care from a geriatrics, obesity medicine, and family medicine perspective, and how federal efforts are working to narrow evidence gaps in diabetes care and prevention.
NIDDK-Funded ResearchAnnouncements:
Drug delays type 1 diabetes in people at high risk A study involving treatment with an anti-CD3 monoclonal antibody (teplizumab), conducted by Type 1 Diabetes TrialNet, finds immunotherapy slows progression to clinical disease by 2 years or more.
Vitamin D does not prevent type 2 diabetes in people at high risk The Vitamin D and Type 2 Diabetes (D2d) study, the largest study to directly examine if daily vitamin D supplementation helps keep people at high risk for type 2 diabetes from developing the disease, reveals that taking a daily vitamin D supplement does not prevent type 2 diabetes in adults at high risk.
For more information on news and events from NIDDK-funded research and programs, visit the NIDDK website.